Program
foralumab
Also written as “Foralumab”, “Foralumab TZLS-401 100 µg” and “Intranasal Foralumab Solution”.
Its studies are mostly in Multiple Sclerosis, Chronic Progressive · Crohn Disease · Multiple Sclerosis · COVID-19 · Non-alcoholic Fatty Liver Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tiziana Life Sciences | 61 open or running | phase 2since Aug 21, 2017 | Aug 21, 2017 | none ahead |
| Light Chain Bioscience - Novimmune | 20 open or running | phase 2since Feb 28, 2008 | Feb 28, 2008 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 28, 2008First study: phase 2 study in Moderate to Severe Crohn's DiseaseNew to Light Chain Bioscience - NovimmuneLight Chain Bioscience - Novimmune · NCT00630643 · 40 enrolled
- Dec 8, 2008Phase 2 study in Acute Renal Transplant RejectionLight Chain Bioscience - Novimmune · NCT00805909 · 12 enrolled · France
- Aug 21, 2017Tiziana Life Sciences's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to Tiziana Life SciencesTiziana Life Sciences · NCT03291249
- Jul 14, 2021Phase 2 study in COVID-19Tiziana Life Sciences · NCT04983446
- Aug 24, 20212 phase 1 studiesTiziana Life Sciences · NCT05028946, NCT05029609
- Feb 2, 2024Phase 2 study in Multiple Sclerosis, Chronic ProgressiveTiziana Life Sciences · NCT06292923 · 54 enrolled · United States
- Feb 12, 2025Phase 2 study in Multiple SclerosisTiziana Life Sciences · NCT06890923 · 55 planned · United States
TargetBeta
“A monoclonal antibody directed against cluster of differentiation 3 (CD3) epsilon, with immunomodulatory activity”NCIt, by rule
“T cell surface glycoprotein CD3 inhibitor”ChEMBL 37, by rule
Other programs on CD3E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etentamig | AbbVie | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| cevostamab | Hoffmann-La Roche | phase 3 | 8 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| pasritamig | Johnson & Johnson | phase 3 | 5 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06890923Multiple Sclerosis · United States | 2 | Recruiting | Tiziana Life Sciences | Apr 30, 2026 | 55 |
| NCT06292923Multiple Sclerosis, Chronic Progressive · United States | 2 | Completed | Tiziana Life Sciences | Sep 17, 2026 | 54 |
| NCT05029609Multiple Sclerosis, Chronic Progressive | 1 | Withdrawn | Tiziana Life Sciences | Nov 2022 | 0 |
| NCT05028946Crohn Disease | 1 | Withdrawn | Tiziana Life Sciences | Jul 7, 2023 | 0 |
| NCT04983446COVID-19 | 2 | Withdrawn | Tiziana Life Sciences | Oct 30, 2022 | 0 |
| NCT03291249Non-alcoholic Fatty Liver Disease | 2 | Withdrawn | Tiziana Life Sciences | Dec 1, 2018 | 0 |
| NCT00805909Acute Renal Transplant Rejection · France | 2 | Completed | Light Chain Bioscience - Novimmune | Jan 2009 | 12 |
| NCT00630643Moderate to Severe Crohn's Disease | 2 | Completed | Light Chain Bioscience - Novimmune | Dec 2007 | 40 |
How it is read
Names in the registry
- “Foralumab”, 4 entries
- “Foralumab TZLS-401 100 µg”, 1 entry
- “Intranasal Foralumab Solution”, 1 entry
- “NI-0401”, 1 entry
- “NI-0401 (anti-CD3 mAB)”, 1 entry
Codes read as this program: TZLS401.
Conditions, from the studies’ own filings
- Multiple Sclerosis, Chronic Progressive, 2 studies
- Crohn Disease, 2 studies
- Multiple Sclerosis, 1 study
- COVID-19, 1 study
- Non-alcoholic Fatty Liver Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.